Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists

The use of Immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers: since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors.

Source: Critical Reviews in Oncology Hematology - July 12, 2018 Category: Cancer & Oncology Authors: Alexander Stein, Moehler Markus, Trojan J örg, Goekkurt Eray, Arndt Vogel Source Type: research